• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Drug class o Market segments o Comparison by Drug class o Nucleoside metabolic inhibitors - Market size and forecast 2019-2024 o Immunomodulators - Market size and forecast 2019-2024 o Photosensitizers - Market size and forecast 2019-2024 o NSAIDs - Market size and forecast 2019-2024 o Market opportunity by Drug class • Customer Landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o APAC - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography o Volume drivers – demand led growth o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o 3M Co. o Almirall SA o Bausch Health Companies Inc. o Biofrontera AG o Hill Dermaceuticals Inc. o LEO Pharma AS o Mylan NV o Nestle SA o Novartis AG o Sun Pharmaceutical Industries Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2019 - 2024 ($ million) • 13: Global market: Year-over-year growth 2019 - 2024 (%) • 14: Five forces analysis 2019 & 2024 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2019 • 21: Other1 - Market share 2019-2024 (%) • 22: Comparison by Other1 • 23: Nucleoside metabolic inhibitors - Market size and forecast 2019-2024 ($ million) • 24: Nucleoside metabolic inhibitors - Year-over-year growth 2019-2024 (%) • 25: Immunomodulators - Market size and forecast 2019-2024 ($ million) • 26: Immunomodulators - Year-over-year growth 2019-2024 (%) • 27: Photosensitizers - Market size and forecast 2019-2024 ($ million) • 28: Photosensitizers - Year-over-year growth 2019-2024 (%) • 29: NSAIDs - Market size and forecast 2019-2024 ($ million) • 30: NSAIDs - Year-over-year growth 2019-2024 (%) • 31: Market opportunity by Other1 • 32: Customer landscape • 33: Market share by geography 2019-2024 (%) • 34: Geographic comparison • 35: North America - Market size and forecast 2019-2024 ($ million) • 36: North America - Year-over-year growth 2019-2024 (%) • 37: APAC - Market size and forecast 2019-2024 ($ million) • 38: APAC - Year-over-year growth 2019-2024 (%) • 39: Europe - Market size and forecast 2019-2024 ($ million) • 40: Europe - Year-over-year growth 2019-2024 (%) • 41: ROW - Market size and forecast 2019-2024 ($ million) • 42: ROW - Year-over-year growth 2019-2024 (%) • 43: Key leading countries • 44: Market opportunity by geography ($ million) • 45: Impact of drivers and challenges • 46: Vendor landscape • 47: Landscape disruption • 48: Industry risks • 49: Vendors covered • 50: Market positioning of vendors • 51: 3M Co. - Overview • 52: 3M Co. - Business segments • 53: 3M Co. - Key offerings • 54: 3M Co. - Key customers • 55: 3M Co. - Segment focus • 56: Almirall SA - Overview • 57: Almirall SA - Product and service • 58: Almirall SA - Key offerings • 59: Almirall SA - Key customers • 60: Almirall SA - Segment focus • 61: Bausch Health Companies Inc. - Overview • 62: Bausch Health Companies Inc. - Business segments • 63: Bausch Health Companies Inc. - Key offerings • 64: Bausch Health Companies Inc. - Key customers • 65: Bausch Health Companies Inc. - Segment focus • 66: Biofrontera AG - Overview • 67: Biofrontera AG - Product and service • 68: Biofrontera AG - Key offerings • 69: Biofrontera AG - Key customers • 70: Biofrontera AG - Segment focus • 71: Hill Dermaceuticals Inc. - Overview • 72: Hill Dermaceuticals Inc. - Product and service • 73: Hill Dermaceuticals Inc. - Key offerings • 74: Hill Dermaceuticals Inc. - Key customers • 75: Hill Dermaceuticals Inc. - Segment focus • 76: LEO Pharma AS - Overview • 77: LEO Pharma AS - Business segments • 78: LEO Pharma AS - Key offerings • 79: LEO Pharma AS - Key customers • 80: LEO Pharma AS - Segment focus • 81: Mylan NV - Overview • 82: Mylan NV - Business segments • 83: Mylan NV - Key offerings • 84: Mylan NV - Key customers • 85: Mylan NV - Segment focus • 86: Nestle SA - Overview • 87: Nestle SA - Business segments • 88: Nestle SA - Key offerings • 89: Nestle SA - Key customers • 90: Nestle SA - Segment focus • 91: Novartis AG - Overview • 92: Novartis AG - Business segments • 93: Novartis AG - Key offerings • 94: Novartis AG - Key customers • 95: Novartis AG - Segment focus • 96: Sun Pharmaceutical Industries Ltd. - Overview • 97: Sun Pharmaceutical Industries Ltd. - Business segments • 98: Sun Pharmaceutical Industries Ltd. - Key offerings • 99: Sun Pharmaceutical Industries Ltd. - Key customers • 100: Sun Pharmaceutical Industries Ltd. - Segment focus • 101: Currency conversion rates for US$ • 102: Research Methodology • 103: Validation techniques employed for market sizing • 104: Information sources • 105: List of abbreviations

3M Co., Almirall SA, Bausch Health Companies Inc., Biofrontera AG, Hill Dermaceuticals Inc., LEO Pharma AS, Mylan NV, Nestle SA, Novartis AG, Sun Pharmaceutical Industries Ltd.